Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gastric Cancer or Gastroesophageal Junction Adenocarcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)UnknownNCT03276156
What this trial is testing

Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer

Who this might be right for
Gastric Cancer
Zhejiang Cancer Hospital 12
Large-scale testing (Phase 3)Looking for participantsNCT07518147
What this trial is testing

A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
Sichuan Baili Pharmaceutical Co., Ltd. 438
Early research (Phase 1)Study completedNCT03517488
What this trial is testing

XmAb®20717 in Subjects With Selected Advanced Solid Tumors

Who this might be right for
MelanomaBreast CarcinomaHepatocellular Carcinoma+25 more
Xencor, Inc. 150
Not applicableLooking for participantsNCT06846996
What this trial is testing

Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China

Who this might be right for
HER2-positive Gastric CancerHER2-positive Gastroesophageal Junction
Daiichi Sankyo 260
Testing effectiveness (Phase 2)UnknownNCT04442984
What this trial is testing

FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III)

Who this might be right for
Gastric Carcinoma Stage IVEsophagogastric Junction Adenocarcinoma Stage IV
Blokhin's Russian Cancer Research Center 326
Testing effectiveness (Phase 2)Ended earlyNCT00683787
What this trial is testing

Docetaxel With or Without Vandetanib in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer

Who this might be right for
Gastric Cancer
Roswell Park Cancer Institute 8
Testing effectiveness (Phase 2)UnknownNCT03959293
What this trial is testing

Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastric Cancer
Federation Francophone de Cancerologie Digestive 107
Early research (Phase 1)Looking for participantsNCT04900818
What this trial is testing

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

Who this might be right for
Solid TumorAdvanced CancerMetastatic Cancer+5 more
I-Mab Biopharma US Limited 330
Large-scale testing (Phase 3)Active Not RecruitingNCT05180734
What this trial is testing

PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer

Who this might be right for
Gastric or Esophagogastric Junction Adenocarcinoma
Shanghai Junshi Bioscience Co., Ltd. 878
Testing effectiveness (Phase 2)UnknownNCT05625737
What this trial is testing

Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma

Who this might be right for
Stomach Neoplasms
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 29
Not applicableApproved For MarketingNCT02307812
What this trial is testing

Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
Eli Lilly and Company
Early research (Phase 1)UnknownNCT05315830
What this trial is testing

HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric

Who this might be right for
Adenocarcinoma - GEJAdenocarcinoma of the Stomach
The First Affiliated Hospital of Bengbu Medical University 10
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06942767
What this trial is testing

Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Qilu Pharmaceutical Co., Ltd. 100
Large-scale testing (Phase 3)Study completedNCT05052801
What this trial is testing

Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
Amgen 547
Testing effectiveness (Phase 2)Study completedNCT00061932
What this trial is testing

Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionDiffuse Adenocarcinoma of the StomachIntestinal Adenocarcinoma of the Stomach+5 more
National Cancer Institute (NCI) 41
Early research (Phase 1)Study completedNCT02572687
What this trial is testing

Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies

Who this might be right for
Gastric CancerGastroesophageal Junction AdenocarcinomaNon-Small Cell Lung Cancer+1 more
Eli Lilly and Company 85
Large-scale testing (Phase 3)Looking for participantsNCT06221748
What this trial is testing

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
RemeGen Co., Ltd. 90
Testing effectiveness (Phase 2)Active Not RecruitingNCT06939452
What this trial is testing

A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression

Who this might be right for
Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Yongxu Jia 37
Large-scale testing (Phase 3)Not Yet RecruitingNCT07677293
What this trial is testing

Retlirafusp Alfa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD-1 Antibody Plus Chemotherapy as First-line Treatment for Advanced Gastric Cancer With Liver Metastases

Who this might be right for
Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
Peking University 332
Testing effectiveness (Phase 2)Study completedNCT02096666
What this trial is testing

A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects

Who this might be right for
Stomach Neoplasms
Amgen 11
Next Page